Payment overview · 2025
General Payments
$2,161.88
61 reported records · 17 companies
Healthcare provider profile · identity verified
Yan Lin, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLORAL PARK, NY · NPI 1831677178
Verified facts
What the public records show
CMS Open Payments records show Yan Lin, NP received $2,161.88 in general payments during 2025 across 61 reported records.
Gilead Sciences, Inc. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Vemlidy by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $619.23 | 28.6% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $408.11 | 18.9% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $340.21 | 15.7% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$178.45 | 8.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $101.57 | 4.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.06 | 3.5% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $57.65 | 2.7% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $52.86 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.26 | 2.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.74 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.31 | 1.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $24.09 | 1.1% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $23.30 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.16 | 1.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.60 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.28 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,161.88 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $205.29 | 10 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $178.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $172.95 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $152.95 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $124.26 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $80.86 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.06 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $60.99 | 3 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $57.65 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.88 | 3 | 2025 |
Source payment records
|
|||||
| SYLVANT Normalized: sylvant |
Drug | RECORDATI_RARE_DISEASES_INC. | $52.86 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $31.57 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 281 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 214 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 88 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
281 | 80 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 59 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 394 |
| Diclofenac Epolamine | Diclofenac Epolamine | 638 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 607 | 212 |
| Losartan Potassium | Losartan Potassium | 579 | 223 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 139 |
| Fluticasone Propionate | Fluticasone Propionate | 328 | 203 |
| Metformin Hcl Er | Metformin Hcl | 313 | 115 |
| Farxiga | Dapagliflozin Propanediol | 281 | 80 |
| Ammonium Lactate | Ammonium Lactate | 274 | 114 |
| Raloxifene Hcl | Raloxifene Hcl | 269 | 85 |
| Montelukast Sodium | Montelukast Sodium | 248 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 87 |
| Famotidine | Famotidine | 230 | 114 |
| Metformin Hcl | Metformin Hcl | 230 | 89 |
| Vascepa | Icosapent Ethyl | 224 | 64 |
| Jardiance | Empagliflozin | 214 | 59 |
| Meclizine Hcl | Meclizine Hcl | 176 | 111 |
| Mometasone Furoate | Mometasone Furoate | 165 | 110 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 157 | 58 |
| Omeprazole | Omeprazole | 153 | 63 |
| Allopurinol | Allopurinol | 146 | 42 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 144 | 40 |
| Finasteride | Finasteride | 129 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 33 |
| Azithromycin | Azithromycin | 118 | 109 |
| Vemlidy | Tenofovir Alafenamide | 112 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 55 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 104 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 37 |
| Simvastatin | Simvastatin | 98 | 27 |
| Donepezil Hcl | Donepezil Hcl | 95 | 32 |
| Celecoxib | Celecoxib | 90 | 61 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 44 |
| Rybelsus | Semaglutide | 88 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 29 |
| Ozempic | Semaglutide | 86 | 23 |
| Ketoconazole | Ketoconazole | 85 | 33 |
| Hydrocortisone | Hydrocortisone | 84 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 36 |
| Januvia | Sitagliptin Phosphate | 78 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 77 | 40 |
| Alendronate Sodium | Alendronate Sodium | 76 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 30 |
| Eliquis | Apixaban | 73 | 22 |
| Bepotastine Besilate | Bepotastine Besilate | 71 | 34 |
| Trazodone Hcl | Trazodone Hcl | 71 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 28 |
| Restasis | Cyclosporine | 67 | 22 |
| Ezetimibe | Ezetimibe | 65 | 25 |
| Lisinopril | Lisinopril | 65 | 25 |
| Lidocaine | Lidocaine | 63 | 31 |
| Linzess | Linaclotide | 63 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 57 | 18 |
| Enalapril Maleate | Enalapril Maleate | 56 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 20 |
| Mupirocin | Mupirocin | 52 | 40 |
| Atenolol | Atenolol | 51 | 22 |
| Gabapentin | Gabapentin | 51 | 33 |
| Carvedilol | Carvedilol | 47 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 47 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 17 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 46 | suppressed |
| Nexium | Esomeprazole Magnesium | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | 13 |
| Ibuprofen | Ibuprofen | 45 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 16 |
| Telmisartan | Telmisartan | 45 | 12 |
| Azelastine Hcl | Azelastine Hcl | 43 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Furosemide | Furosemide | 42 | 11 |
| Glimepiride | Glimepiride | 42 | 13 |
| Loperamide | Loperamide Hcl | 41 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 15 |
| Halobetasol Propionate | Halobetasol Propionate | 37 | 22 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 36 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 16 |
| Myrbetriq | Mirabegron | 35 | 14 |
| Procto-Med Hc | Hydrocortisone | 34 | 17 |
| Ciclopirox | Ciclopirox Olamine | 33 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 12 |
| Entecavir | Entecavir | 31 | suppressed |
| Naproxen | Naproxen | 30 | 24 |
| Lactulose | Lactulose | 28 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | 15 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | 13 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Prednisone | Prednisone | 24 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 12 |
| Colchicine | Colchicine | 23 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 23 | suppressed |
| Baclofen | Baclofen | 22 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Prolia | Denosumab | 19 | 14 |
| Valacyclovir | Valacyclovir Hcl | 19 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,161.88 · 61 records | Gilead Sciences, Inc. | AIRSUPRA, AKEEGA, BALVERSA, BREZTRI, ELIQUIS, ERLEADA, EVENITY, FARXIGA, JARDIANCE, JAYPIRCA, KEYTRUDA, LYNPARZA, Lenvima, Livdelzi, MOUNJARO, NINLARO, NURTEC ODT, Nubeqa, OTEZLA, Ozempic, REPATHA, REZDIFFRA, Rybelsus, SYLVANT, SYMPLICITY G3, SYNTHROID, Stivarga, Trodelvy, UBRELVY, VERZENIO, Vitrakvi, Vonjo, WELIREG, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error